clinical trial · NCT07107126
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Remedy Plan, Inc.·phase1·recruiting·n = 24
Acute Myeloid LeukemiaMyelodysplastic SyndromeRPT1G
brief summary
The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
started
Feb 13, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Mar 25, 2026
official title
A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemia Activity of RPT1G in Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol